Bayer Intensifies Research in Early Diagnosis of Alzheimer's Disease
- Details
- Category: Bayer

Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial
- Details
- Category: Pfizer

New low-dose oral contraceptive YAZ® launched in Europe
- Details
- Category: Bayer

Novo Nordisk launches a next generation of FlexPen®
- Details
- Category: Novo Nordisk

Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon
- Details
- Category: Pfizer

TRANSCEND® trial confirms long-term protective benefits and excellent tolerability profile
- Details
- Category: Boehringer Ingelheim

Anavex completes successful preclinical studies on lead Alzheimer's drug candidate
- Details
- Category: Clinical Trials
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, today announced the successful completion of preclinical studies (in-vitro and in-vivo in mice) on ANAVEX 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer's disease.
More Pharma News ...
- Novartis decides not to pursue further development of Aurograb(TM)
- Rivaroxaban Phase II Data in ACS to be Presented at AHA Congress in November
- Abbott Fund to Build First Pediatric HIV/AIDS Clinic in Tanzania
- GlaxoSmithKline and Valeant Pharmaceuticals announce worldwide collaboration agreement
- Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program
- ADAGIO trial results show Azilect® slows progression of Parkinson's disease
- Brings complementary capabilities in India to address patient populations most at risk